A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)
Brown University
Summary
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Histologically confirmed diagnosis of colorectal adenocarcinoma 2. Surgically unresectable, liver-isolated or liver-dominant, RECIST measurable, metastatic disease 3. Age ≥18 years at the time of signing informed consent 4. ECOG performance status 0 or 1 5. Progression on 2 or more lines of systemic therapy 6. Agreeable to providing tumor tissue and blood for exploratory correlative analyses 7. Less than 50% of liver volume replaced by metastatic disease (as determined by investigator) 8. Demonstrate adequate organ function as defined in table below (all screening labs…
Interventions
- Combination Productyttrium-90 radioembolization
yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Location
- Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals Providence, Rhode Island, United States, 02903 Contact:Providence, Rhode Island